Osteopenic syndrome in type 1 diabetes mellitus
https://doi.org/10.14341/osteo13220
Abstract
Type 1 diabetes mellitus is a chronic metabolic disease that currently retains relevance and high medical and social significance, which is associated not only with its widespread occurrence, but also with a high risk of complications. Osteopenia and osteoporosis are systemic diseases of the skeleton, characterized by a decrease in bone mineral density, which leads to a high risk of fractures, even with minor injuries. Osteopathies are a common manifestation of endocrine organ pathology, including type 1 diabetes.
The article discusses the main mechanisms of the development of osteopenic syndrome in DM1. An analysis of domestic and foreign literature sources has shown that immune factors, impaired phosphorus-calcium metabolism as a result of chronic hyperglycemia, accumulation of glycolysis end products, decreased levels of insulin, amylin, and 25(ОН)D deficiency play a significant role in the formation of bone pathology in type 1 diabetes. In addition to the direct effect of diabetes on bone cells and the bone matrix, the risk of osteopenic syndrome is influenced by diabetic complications that occur in various body systems. Consideration of the cellular and molecular mechanisms of the formation of osteopenic syndrome associated with diabetes expands the understanding of this problem, thereby allowing not only to develop diagnostic criteria, but also to propose effective methods of prevention and treatment.
About the Authors
R. A. Atanesyan
Stavropol State Medical University
Russian Federation
Russian Federation
Roza A. Atanesyan, PhD of Medical Sciences
310 Mira street, 355017 Stavropol
G. N. Ambartsumyan
Stavropol State Medical University
Russian Federation
Russian Federation
Gretta N. Ambartsumyan
Stavropol
L. Y. Klimov
Stavropol State Medical University
Russian Federation
Russian Federation
Leonid Y. Klimov, MD, Professor, Head of the department of faculty pediatrics
Stavropol
S. V. Dolbnya
Stavropol State Medical University
Russian Federation
Russian Federation
Svetlana V. Dolbnya, MD, PhD
Stavropol
G. A. Saneeva
Stavropol State Medical University
Russian Federation
Russian Federation
Galina A. Saneeva, PhD of Medical Sciences, Docent
Stavropol
References
1. Peterkova VA, Shestakova MV, Bezlepkina OB, Laptev DN, Kuraeva TL. Type 1 diabetes mellitus in children. Saharnyj diabet. 2020;23(S1):4–40 (In Russ.)
2. Laptev DN, Bezlepkina OV., Sheshko EL, Aleksandrova GA, et al. Main epidemiologic indicators of type 1 diabetes mellitus in children in the Russian Federation for 2014-2023. Problemy Jendokrinologii. 2024;70(5):76-83 (In Russ.) doi: https://doi.org/10.14341/probl13515
3. Dedov II, Shestakova MV, Vikulova OK, i dr. Diabetes mellitus in the Russian Federation: dynamics of epidemiologic indicators according to the Federal Diabetes Mellitus Register for the period 2010-2022. // Saharnyj diabet. 2023;26(2):104–123 (In Russ.) doi: https://doi.org/10.14341/DM13035
4. Peterkova VA, Bezlepkina OB, Laptev DN, i dr., Rossijskaya associaciya ehndokrinologov. Clinical recommendations. Type 1 diabetes mellitus in children; 2025 (In Russ.).
5. Mal'cev SV, Mansurova GSh. Decreased bone mineral density in children and adolescents: causes, incidence of development, and treatment. Voprosy sovremennoj pediatrii. 2015;14(5):573-578 (In Russ.) doi: https://doi.org/10.15690/vsp.v14i5.1442
6. Kiseleva NG, Taranushenko TE, Golubenko NK. Diagnosis of osteoporosis in childhood. Medicinskij sovet. 2020;1:179-186 doi: https://doi.org/10.21518/2079-701X-2020-1-186-193
7. Belaja ZhE, Belova KJu, Birjukova EV, et al. Federal clinical recommendations on the diagnosis, treatment and prevention of osteoporosis. Osteoporoz i osteopatii. 2021;24(2):4-47 doi: https://doi.org/10.14341/osteo12930
8. Verbovoj AF, Pashenceva AV, Sharonova LA. Osteoporosis: current state of the problem. Terapevticheskij arhiv. 2017;5:90-97 doi: https://doi.org/10.17116/terarkh201789590-97
9. Kalandija MM, Tokmakova AJu, Galstjan G R. Role of glycation end products in the development and progression of diabetic neuroosteoarthropathy. Problemy endokrinologii. 2021;3:4-9 doi: https://doi.org/10.14341/probl12778
10. Thong EP, Herath M, Weber DR, et all. Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: A systematic review and meta-analysis. Clinical endocrinology. 2018;89(3):314–323. doi: https://doi.org/10.1111/cen.13761
11. Vilaca T, Schini M, Harnan S, et all. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update. Bone. 2020;137:115457. doi: https://doi.org/10.1016/j.bone.2020.115457
12. Wang H, Ba Y, Xing Q, et all. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ. 2019;9(1):024067. doi: https://doi.org/10.1136/bmjopen-2018-024067
13. Guder C, Gravius S, Burger C, et all. Osteoimmunology: a current update of the interplay between bone and the immune system. Front Immunol. 2020;11:58-60. doi: https://doi.org/10.3389/fimmu.2020.00058
14. Hygum K, Starup-Linde J, Harslof T, et all. Mechanisms in endocrinology: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. European Journal of Endocrinology. 2017;176(3):137-157. doi: https://doi.org/10.1530/EJE-16-0652
15. Madsen JOB, Herskin CW, Zerahn B, et all. Decreased markers of bone turnover in children and adolescents with type 1 diabetes. Pediatric diabetes. 2020;21(3):505–514. doi: https://doi.org/10.1111/pedi.12987
16. Schacter GI, Leslie WD. Diabetes and Osteoporosis: Part I, Epidemiology and Pathophysiology. Endocrinology and Metabolism Clinics of North America. 2021;50(2):275–285. doi: https://doi.org/10.1016/j.ecl.2021.03.005
17. Wang T, He C. TNF-α and IL-6: the link between immune and bone system. Current Drug Targets. 2020;21(3):213–227. doi: https://doi.org/10.2174/1389450120666190821161259
18. Devaraja J, Jacques R, Paggiosi M, Clark C, Dimitri P. Impact of Type 1 Diabetes Mellitus on Skeletal Integrity and Strength in Adolescents as Assessed by HRpQCT. JBMR Plus. 2020;4(11):10422. doi: https://doi.org/10.1002/jbm4.10422
19. Sochett EB, Dominicis M, Vali R, Shammas A, Elia Y, Moineddin R, et all. Relationship between risk factors for impaired bone health and HR-pQCT in young adults with type 1 diabetes. Front Endocrinol (Lausanne). 2023;14:1144137. doi: https://doi.org/10.3389/fendo.2023.1144137
20. Li Z, Wang X, Hong TP, Wang HJ, Gao ZY, Wan M. Advanced glycosylation end products inhibit the proliferation of bone-marrow stromal cells through activating MAPK pathway. European Journal of Medical Research. 2021;26(1):94. doi: https://doi.org/10.1186/s40001-021-00559-x
21. Wu B, Fu Z, Wang X, Zhou P, Yang Q, Jiang Y, et all. A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment. Frontiers in Endocrinology. 2022;13:1-9 doi: https://doi.org/10.3389/fendo.2022.1052592
22. Wang Y, Jiang C, Shang Z, Qiu G, Yuan G, Xu K, et all. AGEs/RAGE Promote Osteogenic Differentiation in Rat Bone Marrow-Derived Endothelial Progenitor Cells via MAPK Signaling. Journal of Diabetes Research. 2022: 4067812. doi: https://doi.org/10.1155/2022/4067812
23. Li Y, Shrestha A, Zhang H, Li L, Li D, Fu T, et all. Impact of diabetes mellitus simulations on bone cell behavior through in vitro models. Journal of Bone and Mineral Metabolism. 2020;38(5):607–619. doi: https://doi.org/10.1007/s00774-020-01101-5
24. Luo M, Zhao Z, Yi J. Osteogenesis of bone marrow mesenchymal stem cell in hyperglycemia. Frontiers in Endocrinology. 2023;14:1150068. doi: https://doi.org/10.3389/fendo.2023.1150068
25. Larina II, Severina AS, Maganeva IS, et al. Glycation end products and oxidative stress as the basis of metabolic abnormalities in patients with type 1 diabetes mellitus after successful co-transplantation of kidney and pancreas. Terapevticheskij arhiv. 2021;10:1155-1163 (In Russ.) doi: https://doi.org/10.26442/00403660.2021.10.201100
26. Borzyh OB, Shnaider NA, Karpova EI, et al. Collagen synthesis in the skin, its functional and structural features. Medicinskij vestnik Severnogo Kavkaza. 2021;16(4):443-450 (In Russ.) doi: https://doi.org/10.1177/1538574417698905
27. Demidova TJu, Plahotnjaja VM. Diabetes mellitus and osteoporosis: pathogenetic relationship and modern principles of treatment. Medicinskij Sovet. 2021;7:96-107 (In Russ.) doi: https://doi.org/10.21518/2079-701X-2021-7-96-107
28. Efremenkova AS, Krutikova NJu. Bone pathology in children with endocrine disorders. Vjatskij medicinskij vestnik. 2021;1(69):81-87 (In Russ.) doi: https://doi.org/10.24411/2220-7880-2021-10158
29. Tanaka K, Yamaguchi T, Kanazawa I, et all. Effects of high glucose and advanced glycation endproducts on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461(2):193–199. doi: https://doi.org/.1016/j. bbrc.2015.02.091
30. Zhaoyang GM, Fan LI, Fengzhen QO, et all. Causal associations between insulin-like growth factor 1 and vitamin D levels: a two-sample bidirectional Mendelian randomization study. Frontiers in Nutrition. 2023;10:98-100. doi: https://doi.org/10.3389/fnut.2023.1162442
31. Fang J, Zhang X, Chen X, et all. The role of insulin-like growth factor-1 in bone remodeling: A review. International Journal of Biological Macromolecules. 2023;238:124125. doi: https://doi.org/10.1016/j.ijbiomac.2023.124125
32. Canalis E. Management of endocrine disease: Novel anabolic treatments for osteoporosis. European Journal of Endocrinology. 2018;178(2):33-44. doi: https://doi.org/10.1530/EJE-17-0920
33. Ouquerke A, Blulel J. Osteoblasts and insulin: an overview. Journal of Biological Regulators and Homeostatic Agents. Advance online publication. 2020;35(1)
34. Safarova SS. The role of amylin in the development of diabetic osteopathy. Kazanskij medicinskij zhurnal. 2017;5:813-816 (In Russ.) doi: https://doi.org/10.1016/j.autrev.2013.10.005
35. Hieronymus L, Griffin S. Role of amylin in type 1 and type 2 Diabetes. The Diabetes Educator. 2015;41(1):47-56. doi: https://doi.org/10.1177/0145721715607642
36. Efremenkova AS, Krutikova NJu. Features of osteopenic syndrome in children with type 1 diabetes mellitus. Fundamental'nye issledovanija v pediatrii. 2021;4:52-53 (In Russ.)
37. Hough FS, Pierroz DD, Cooper C. Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur. J. Endocrinol. 2016;174(4):127–138. doi: https://doi.org/10.1530/EJE-15-0820
38. Wang T, He C. TNF-α and IL-6: The Link between Immune and Bone System. Current Drug Targets. 2020;21(3):213–227. doi: https://doi.org/10.2174/1389450120666190821161259
39. Sims NA. Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption. The international journal of biochemistry & cell biology. 2016;79:14-23. doi: https://doi.org/10.1016/j.biocel.2016.08.003
40. Marino M, Galeazzi T, Gesuita R, et all. Differences in Plasma 25-Hydroxyvitamin D Levels at Diagnosis of Celiac Disease and Type 1 Diabetes. Nutrients. 2024;16(5):743. doi: https://doi.org/10.3390/nu16050743
41. Zakharova IN, Mal'cev SV, Klimov LYA, et all. The effect of vitamin D on the body's immune response. Pediatriya. Consilium Medicum. 2020;2:29-37 (In Russ.). doi: https://doi.org/10.26442/26586630.2020.2.200238
42. Wimalawansa SJ. Physiology of Vitamin D-Focusing on Disease Prevention. Nutrients. 2024;16(11):1666. doi: https://doi.org/10.3390/nu16111666
43. Povaljaeva AA, Pigarova EA, Dzeranova LK, Rozhinskaja LJa. Relationship of vitamin D status with the development and course of type 1 diabetes mellitus. Ozhirenie i metabolizm. 2020;17(1):82-87 (In Russ.) doi: https://doi.org/10.14341/omet12206
44. Vengrzhinovskaja OI, Bondarenko IZ, Shackaja OA, Nikankina LV, et all. Adipokines and cardiorespiratory system in young patients with type 1 diabetes mellitus. Terapevticheskij arhiv. 2022;94(10):1143-1148 (In Russ.) doi: https://doi.org/10.26442/00403660
Supplementary files
|
|
1. Рисунок 1. Упрощенная схема влияния гипергликемии на метаболизм костной ткани. | |
| Subject | ||
| Type | Other | |
View
(237KB)
|
Indexing metadata ▾ | |
|
|
2. Рисунок 2. Влияние КПГ на соединительную ткань. | |
| Subject | ||
| Type | Other | |
View
(426KB)
|
Indexing metadata ▾ | |
Review
For citations:
Atanesyan R.A., Ambartsumyan G.N., Klimov L.Y., Dolbnya S.V., Saneeva G.A. Osteopenic syndrome in type 1 diabetes mellitus. Osteoporosis and Bone Diseases. 2025;28(4):32-39. (In Russ.) https://doi.org/10.14341/osteo13220
Views:
202
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
